【摘 要】
：
CPRC1 is a novel investigated proton pump inhibitor, which shows dramaticsuccess in the management of acid-related disorders.Now this drug is being develope
【机 构】
：
Clinical Pharmacology Research Center, Peking Union Medical College Hospital,Chinese Academy of Medi
【出 处】
：
2015年第一届药代动力学朝阳论坛
论文部分内容阅读
CPRC1 is a novel investigated proton pump inhibitor, which shows dramaticsuccess in the management of acid-related disorders.Now this drug is being developed in Phase Ⅱ study in China.In this paper for the first time, a population pharmacokinetic (PopPK) model was developed to describe the PK characters of CPRC1 in patients with duodenal ulcer after receiving 20 mg CPRC1 intravenously.Plasma samples were collected and concentrations of CPRC1 were detected by a validated UPLC-MS/MS method.The PopPK model was developed using Phoenix NLME 1.2 with a non-linear mixed-effect model, and the following covariates were tested: weight, height, age, gender, alanine aminotransferase (ALT), aspartate aminotransferase (AST),total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), creatinine (CR) and genotype of CYP2C19.Covariate effects on parameters describing the pharmacokinetics relationship were screened using stepwise forward inclusion/backward elimination.
其他文献
Drug ADME experiment in humans is a pivotal drug metabolism study in support of drug development and registration.Human ADME study provides information on t
Catechol-O-methyltransferase (COMT) plays a central role in the metabolic inactivation of endogenous catechols including catecholic neurotransmitters and es
TPN729MA is a novel selective phosphodiesterase type 5 (PDE5) inhibitor.The preclinical PK of TPN729MA was studied in rats and dogs.Human clearance (CL) val
When evaluating clinical drug-drug interactions (DDI), revealing whether and how the role of the metabolic status in the entire drug disposition in vivo aff
The circulating microRNAs (miRNAs) own many characteristics of biomarkers and can be released from platelet.We hypothesize plasma miRNA level can reflect th
Our study aimed at the investigation of in vivo anticancer effect of the combination use of dexamethasone (DEX) and gemcitabine (GM) as well as the developm
Drug metabolism has become an integral part of drug discovery and development from the earliest stage, and this change may have been driven by the evolution
Diosbulbin B (DIOB) is the most abundant component of Dioscorea bulbifera L.(DB), a traditional Chinese medicine herb.DIOB and DB extracts have been reporte
The recognition of the gut microbiota-host metabolic axis and its implications in human metabolic disease has highlighted the contribution of the gut microb
LAT1 overexpressed on membrane of various tumor cells, are potential targets for tumor-targeting therapy.This study aimed to develop a LAT1-mediated drug de